Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Guerbet (GBT) EUR1

Sell:€28.65 Buy:€31.50 Change: €1.00 (3.33%)
Market closed |  Prices as at close on 5 August 2020 | Switch to live prices |
Change: €1.00 (3.33%)
Market closed |  Prices as at close on 5 August 2020 | Switch to live prices |
Change: €1.00 (3.33%)
Market closed |  Prices as at close on 5 August 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

Contact details

15 rue des Vanesses, Zone Paris Nord II
+33 (1) 45915000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€377.88 million
Shares in issue:
12.55 million
Health Care Supplies
Euronext Paris

Key personnel

  • Marie-Claire Janailhac-Fritsch
    Independent Chairman of the Board
  • David Hale
    Chief Executive Officer, & Chief Commercial Officer ad interim, Member of the Executive Committee
  • Pierre Andre
    Chief Pharmaceutical Officer, Deputy Chief Executive Officer
  • Jerome Estampes
    Chief Financial Officer, Member of the Executive Committee
  • Petra Zalabak
    Vice President of Human Resources, Member of the Executive Committee
  • Philippe Bourrinet
    Vice President, Development, Medical & Regulatory Affairs, Member of the Executive Committee
  • Claire Corot
    Vice President - Research, Innovation and Business Development, Member of the Executive Committee
  • Jean-Francois Blanc
    Director of Technical Operations, Member of the Executive Committee
  • Francois Nicolas
    Chief Digital Officer, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.